Unknown

Dataset Information

0

Serum free light chains, not urine specimens, should be used to evaluate response in light-chain multiple myeloma.


ABSTRACT: Guidelines for monitoring multiple myeloma (MM) patients expressing light chains only (light-chain MM [LCMM]) rely on measurements of monoclonal protein in urine. Alternatively, serum free light chain (sFLC) measurements have better sensitivity over urine methods, however, demonstration that improved sensitivity provides any clinical benefit is lacking. Here, we compared performance of serum and urine measurements in 113 (72κ, 41λ) newly diagnosed LCMM patients enrolled in the Intergroupe Francophone du Myélome (IFM) 2009 trial. All diagnostic samples (100%) had an abnormal κ:λ sFLC ratio, and involved (monoclonal) FLC (iFLC) expressed at levels deemed measurable for monitoring (≥100 mg/L). By contrast, only 64% patients had measurable levels of monoclonal protein (≥200 mg per 24 hours) in urine protein electrophoresis (UPEP). After 1 and 3 treatment cycles, iFLC remained elevated in 71% and 46% of patients, respectively, whereas UPEP reported a positive result in 37% and 18%; all of the patients with positive UPEP at cycle 3 also had elevated iFLC levels. Importantly, elevated iFLC or an abnormal κ:λ sFLC ratio after 3 treatment cycles associated with poorer progression-free survival (P = .006 and P < .0001, respectively), whereas positive UPEP or urine immunofixation electrophoresis (uIFE) did not. In addition, patients with an abnormal κ:λ sFLC ratio had poorer overall survival (P = .022). Finally, early normalization of κ:λ sFLC ratio but not negative uIFE predicted achieving negative minimal residual disease, as determined by flow cytometry, after consolidation therapy (100% positive predictive value). We conclude that improved sensitivity and prognostic value of serum over urine measurements provide a strong basis for recommending the former for monitoring LCMM patients.

SUBMITTER: Dejoie T 

PROVIDER: S-EPMC5179336 | biostudies-literature | 2016 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Serum free light chains, not urine specimens, should be used to evaluate response in light-chain multiple myeloma.

Dejoie Thomas T   Corre Jill J   Caillon Helene H   Hulin Cyrille C   Perrot Aurore A   Caillot Denis D   Boyle Eileen E   Chretien Marie-Lorraine ML   Fontan Jean J   Belhadj Karim K   Brechignac Sabine S   Decaux Olivier O   Voillat Laurent L   Rodon Philippe P   Fitoussi Olivier O   Araujo Carla C   Benboubker Lotfi L   Fontan Charlotte C   Tiab Mourad M   Godmer Pascal P   Luycx Odile O   Allangba Olivier O   Pignon Jean-Michel JM   Fuzibet Jean-Gabriel JG   Legros Laurence L   Stoppa Anne Marie AM   Dib Mamoun M   Pegourie Brigitte B   Orsini-Piocelle Frederique F   Karlin Lionel L   Arnulf Bertrand B   Roussel Murielle M   Garderet Laurent L   Mohty Mohamad M   Meuleman Nathalie N   Doyen Chantal C   Lenain Pascal P   Macro Margaret M   Leleu Xavier X   Facon Thierry T   Moreau Philippe P   Attal Michel M   Avet-Loiseau Herve H  

Blood 20161011 25


Guidelines for monitoring multiple myeloma (MM) patients expressing light chains only (light-chain MM [LCMM]) rely on measurements of monoclonal protein in urine. Alternatively, serum free light chain (sFLC) measurements have better sensitivity over urine methods, however, demonstration that improved sensitivity provides any clinical benefit is lacking. Here, we compared performance of serum and urine measurements in 113 (72κ, 41λ) newly diagnosed LCMM patients enrolled in the Intergroupe Franco  ...[more]

Similar Datasets

| S-EPMC7995444 | biostudies-literature
| S-EPMC9748693 | biostudies-literature
| S-EPMC4815727 | biostudies-literature
| S-EPMC9812726 | biostudies-literature
| S-EPMC6128544 | biostudies-literature
| S-EPMC6783946 | biostudies-literature
| S-EPMC4598254 | biostudies-literature
| S-EPMC6949235 | biostudies-literature
| S-EPMC7431983 | biostudies-literature
| S-EPMC2834393 | biostudies-literature